NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
12 trialsNCT02787642 2026-02-25
RADIOSARP
Institut Bergonié
Phase 1 Completed
NCT04417062 2026-02-25
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05156268 2025-08-17
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT01390571 2018-02-05
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
Cancer Research UK
Phase 1 Completed
NCT01583543 2017-05-19
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Massachusetts General Hospital
Phase 2 Completed